

Contents

Symbols and abbreviations	i
List of tables	ii
List of figures	v
1. INTRODUCTION	1
2. NEED FOR THE STUDY	13
3. OBJECTIVES	14
4. REVIEW OF LITERATURE	
4.1 Introduction to oral cavity	15
4.1.1 Oral cavity	15
4.1.2 Overview of oral cavity	15
4.1.3 Anatomy of oral mucosa	16
4.1.4 Biochemistry of oral mucosa	17
4.1.5 Routes of drug transport across the oral mucosa	18
4.1.6 Barriers to drug transport across buccal mucosa	19
4.2 Buccal as a site of drug delivery	21
4.2.1 Advantages of mucoadhesive buccal drug delivery System	22
4.2.2 Limitation of buccal drug administration	23
4.3. Formulations	24
4.3.1 Solid buccal adhesive dosage forms	24
4.3.2 Semi-solid buccal adhesive dosage forms	25
4.3.3 Liquid dosage forms	26

4.4 Introduction to vagina	26
4.4.1 Anatomy and histology of vagina	26
4.4.2 Physiological changes and the influence of drug absorption	28
4.4.3 Vaginal secretions	28
4.4.4 Vaginal pH	29
4.4.5 Microflora	29
4.4.6 Cyclic changes	29
4.5 Vagina as site for drug therapy	30
4.5.1 Advantages of vaginal drug delivery	30
4.5.2 Drawbacks of vaginal drug delivery	32
4.6 Formulations	32
4.6.1 Vaginal semisolids	32
4.6.2 Vaginal suppositories	32
4.6.3 Vaginal liquids	33
4.6.4 Vaginal aerosols	33
4.6.5 Vaginal rings	33
4.6.6 Vaginal inserts	33
4.6.7 Insitu gelling	34
4.6.8 Medicated vaginal tampons	34
4.6.9 Vaginal films	34
4.7 Introduction to rectum	
4.7.1 Physiology and biopharmaceutical characteristics of rectum	35
4.7.2 Permeability	35

4.7.3 Effect of pH	37
4.8 Rectal drug delivery	
4.8.1 Advantages	38
4.8.2 Disadvantages	38
4.9 Formulations	
4.9.1 Rectal semisolids	38
4.9.2 Rectal suppositories	39
4.9.3 Rectal liquids	40
4.10 Bioadhesion	40
4.10.1 Mechanism of bioadhesion	41
4.10.2 Theories of bioadhesion/mucoadhesion	42
4.10.3 Factors affecting bioadhesion/mucoadhesion	44
4.10.4 Possible routes of drug transport across the oral mucosa	45
4.10.5 Permeation enhancers	46
4.10.6 Mechanism of buccal absorption enhancer	47
4.11 Review of Research Papers	49
4.12 Drugs Profile	58
4.13 Polymers Profile	61
4.14 Excipients Profile	66
5 MATERIALS AND METHODS	
5.1 Materials	70
5.2 Instruments and Equipments	72
5.3 Preparation of buffer solutions	74

5.4 Analytical methods	
5.4.1 Estimation of Miconazole nitrate (MN)	75
5.4.2 Estimation of 5-fluorouracil(5-FU)	79
5.5 Preformulation studies	85
5.6 Formulation design for MN matrix tablet	
Chitosan-carbopol 71G IPEC	
5.6.1 Preparation of chitosan-carbopol 71G IPEC	88
5.6.2 Turbidity measurement of chitosan-carbopol 71G IPEC ratios	88
5.6.3 MN matrix tablet of using chitosan- carbopol 71G IPEC	88
Chitosan-carboxymethyltamarind (CMT) IPEC	
5.6.4 Preparation of chitosan-CMT IPEC	90
5.6.5 Viscosity measurement of chitosan-CMT IPEC ratios	90
5.6.6 MN matrix tablet of using chitosan-CMT IPEC	90
5.7 Formulation design for 5-FU matrix tablets	
Chitosan-polycarbophil IPEC	
5.7.1 Preparation of chitosan-polycarbophil IPEC	92
5.7.2 Transmittance measurement of chitosan-polycarbophil IPEC ratios	92
5.7.3 5-FU matrix tablet using chitosan-polycarbophil IPEC	92
Chitosan-sodium alginate IPEC	
5.7.4 Preparation of chitosan-sodium alginate IPEC	94
5.7.5 Viscosity measurement of chitosan-sodium alginate IPEC ratios	94

5.7.3	5-FU matrix tablet using chitosan-sodium alginate IPEC	94
5.8 Evaluation		
5.8.1	Characterization of IPEC	96
5.8.2	Evaluation of tablets	
5.6.2.1	Physicochemical properties	96
5.6.2.2	Swelling studies	98
5.6.2.3	<i>In vitro</i> dissolution studies	98
5.6.2.4	<i>In vitro</i> mucoadhesion studies	99
5.6.2.5	Ex vivo permeation studies	100
5.6.2.6	Mathematical model fitting	100
5.9 <i>In vivo</i> Evaluation		
5.9.1	X-ray photographic studies	101
5.10	Stability Studies	102
6	RESULTS AND DISCUSSION	
6.1	Miconazole nitrate matrix tablet	
6.1.1	Preformulation studies	103
6.1.2	Turbidity measurement of Chitosan-carbopol IPEC ratios	107
6.1.3	Characterization of chitosan-carbopol IPEC	
6.1.3.1	FT-IR	108
6.1.3.2	DSC	113
6.1.3.3	X-ray diffraction	116
6.1.4	Evaluation of MN tablets	118
6.1.5	Swelling studies	120

6.1.6 <i>In vitro</i> dissolution Studies	126
6.1.7 <i>In vitro</i> mucoadhesion studies	133
6.1.8 <i>In vivo</i> X-ray studies	135
6.1.9 Mathematical model fitting	137
6.2.10 Stability studies	138
6.2 Miconazole nitrate matrix tablet	
6.2.1 Preformulation studies	139
6.2.2 Viscosity measurement of chitosan-CMT IPEC	142
6.2.3 Characterization of chitosan-CMT IPEC	
6.2.3.1 FT-IR	143
6.2.3.2 DSC	147
6.2.3.3 X-ray diffraction	148
6.2.4 Evaluation of MN tablets	150
6.2.5 Swelling studies	152
6.2.6 <i>In vitro</i> dissolution Studies	159
6.2.7 <i>In vitro</i> mucoadhesion studies	166
6.2.8 <i>In vivo</i> X-ray studies	168
6.2.9 Mathematical model fitting	169
6.2.10 Stability studies	170
6.3 5-fluorouracil matrix tablet	
6.3.1 Preformulation studies	171
6.3.2 Transmittance measurement of chitosan-polycarbophil IPEC ratios	175

6.3.3 Characterization of chitosan-polycarbophil IPEC	
6.3.3.1 FT-IR	176
6.3.3.2 DSC	180
6.3.3.3 X-ray diffraction	182
6.3.4 Evaluation of 5-FU tablets	184
6.3.5 Swelling studies	186
6.3.6 <i>In vitro</i> dissolution Studies	194
6.3.7 <i>In vitro</i> mucoadhesion studies	203
6.3.8 <i>In vivo</i> X-ray studies	205
6.3.9 Ex vivo permeation studies	206
6.3.10 Mathematical model fitting	208
6.3.11 Stability studies	209
6.4 5-fluorouracil matrix tablet	
6.4.1 Preformulation studies	210
6.4.2 Viscosity measurement of chitosan-sodium alginate IPEC ratios	213
6.4.3 Characterization of chitosan-sodium alginate IPEC	
6.4.3.1 FT-IR	214
6.4.3.2 DSC	218
6.4.3.3 X-ray diffraction	222
6.4.4 Evaluation of 5-FU tablets	224
6.4.5 Swelling studies	226
6.4.6 <i>In vitro</i> dissolution Studies	235

6.4.7	<i>In vitro</i> mucoadhesion studies	245
6.4.8	<i>In vivo</i> X-ray studies	247
6.4.9	Ex vivo permeation studies	249
6.4.10	Mathematical model fitting	251
6.4.11	Stability studies	252
7	SUMMARY AND CONCLUSION	253
8	BIBLIOGRAPHY	260
9	ANNEXURE	
	Animal Ethical clearance Certificate	289
	Publications	290
	Published articles	291